Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

INNATE PHARMA: Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting

Read more ››
By: Nasdaq / GlobenewsWire - 05 Dec 2016
Related companies:  Innate Pharma S.A.

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

SHANGHAI, Dec. 5, 2016 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development... Read more ››

By: PR Newswire Association LLC. - 05 Dec 2016
Related companies:  Sanofi S.A.

Asia Plantation Capital Berhad Proudly Confirms Status as a Bioeconomy Company

KUALA LUMPUR, Malaysia, Dec. 5, 2016 /PRNewswire/ -- As leaders in the field of sustainable plantation management and agarwood production, Asia Plantation Capital Berhad -- the Malaysian arm of the APC Group -- is proud to confirm that its project, 'Production and Commercialisation of High-value... Read more ››

By: PR Newswire Association LLC. - 05 Dec 2016

Medical Robotics Market to Grow at 21.43% CAGR by 2021F, Surgical Robots Drives the Growth Compared to Other Segments

PUNE, India, December 5, 2016 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 05 Dec 2016

ACCL Announces Pesticide Warning for Cannabis in North America

OAKLAND, Calif., Dec. 5, 2016 /PRNewswire/ -- The Association of Commercial Cannabis Laboratories, Inc. (ACCL) released a statement today offering information on the continuing concern of pesticide contamination on Cannabis.

Read more ››
By: PR Newswire Association LLC. - 05 Dec 2016

BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MND

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 5, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today data from the Company's Phase 2 study of NurOwn(®) in ALS, will be highlighted... Read more ››

By: PR Newswire Association LLC. - 05 Dec 2016
Related companies:  BrainStorm Cell Therapeutics Inc.

Considerable Additional Benefit of Eisai's Halaven® (eribulin) in Advanced Liposarcoma Confirmed by the German Federal Joint Committee (G-BA)

HATFIELD, England, December 4, 2016 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 05 Dec 2016

Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma

NORTH CHICAGO, Ill., Dec. 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies evaluating ibrutinib (IMBRUVICA®) as a combination therapy in two of the most common types of non-Hodgkin's... Read more ››

By: PR Newswire Association LLC. - 05 Dec 2016
Related companies:  AbbVie Inc.

Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

CAMBRIDGE, Mass., Dec. 4, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced data from its ongoing Phase 1 trial evaluating BLU-285, an investigational... Read more ››

By: PR Newswire Association LLC. - 05 Dec 2016
Related companies:  Blueprint Medicines

SystemOne and Daktari Announce Partnership to Bring Connected Diagnostics to Developing World

SPRINGFIELD, Mass. and CAMBRIDGE, Mass. and CAPE TOWN, South Africa, Dec. 4, 2016 /PRNewswire/ -- SystemOne, a company focused on connecting diagnostics and providing connected diagnostics software platforms for the developing world, and Daktari Diagnostics, a company focused on making "Anywhere.... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  Daktari Diagnostics, Inc.

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients

RIDGEFIELD, Conn., Dec. 4, 2016 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new analysis of the GLORIA(TM)-AF Registry Program, which showed that newly diagnosed non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  Boehringer Ingelheim Pharmaceuticals, Inc | Boehringer Ingelheim - BD & Licensing | Boehringer Ingelheim Fremont, Inc.

Marapharm Ventures Inc. Pays Off Mortgage on Las Vegas, Nevada Property

KELOWNA, British Columbia, December 4, 2016 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 04 Dec 2016

New Data for Once-daily Adjunctive Zebinix® (eslicarbazepine acetate) Show Good Seizure Control and Tolerability in People With Partial Onset (Focal) Seizures

PORTO, Portugal and HATFIELD, England, December 4, 2016 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 04 Dec 2016

CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 3, 2016 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION(®) [Coagulation Factor IX (Recombinant),... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  CSL Limited

IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy

NORTH CHICAGO, Ill., Dec. 3, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA® (ibrutinib) use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  AbbVie Inc.

Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

SAN DIEGO AND RARITAN, N.J., Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results to date of patients treated with IMBRUVICA(®) (ibrutinib) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showing... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  Janssen Biotech, Inc. | Janssen Research & Development, LLC

In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia

SAN DIEGO, Dec. 3, 2016 /PRNewswire-USNewswire/ -- A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children's Hospital of Philadelphia today reported new results... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016

Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL

EAST HANOVER, N.J., Dec. 3, 2016 /PRNewswire/ -- Findings from a Novartis clinical trial (ELIANA) evaluating efficacy and safety of CTL019, an investigational chimeric antigen receptor T cell (CAR T) therapy, in relapsed/refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic... Read more ››

By: PR Newswire Association LLC. - 04 Dec 2016
Related companies:  Genomics Institute of the Novartis Research Foundation

uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

Read more ››
By: Nasdaq / GlobenewsWire - 03 Dec 2016
Related companies:  uniQure N.V. | uniQure GmbH | uniQure, Inc.

NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors

Read more ››
By: Nasdaq / GlobenewsWire - 03 Dec 2016
Related companies:  The Novo Nordisk Foundation Center for Biosustainability
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑